The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
Immune checkpoint blockade (ICB) has become a standard treatment for non-small cell lung cancer (NSCLC).However, most patients with NSCLC do not benefit from these treatments.Abnormal vasculature is layer cake chardonnay 2020 a hallmark of solid tumors and is involved in tumor immune escape.These abnormalities stem from the increase in the expressi